| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jimmy Li, Cassandra C Areal, Dènahin Hinnoutondji Toffa, Daphné Citherlet, Charles Deacon, Didier Jutras-Aswad, Mark Robert Keezer, Dang Khoa Nguye. Use of non-medical cannabis in epilepsy: A scoping review. Frontiers in neurology. vol 14. 2023-03-23. PMID:36949852. |
use of non-medical cannabis in epilepsy: a scoping review. |
2023-03-23 |
2023-08-14 |
Not clear |
| Jimmy Li, Cassandra C Areal, Dènahin Hinnoutondji Toffa, Daphné Citherlet, Charles Deacon, Didier Jutras-Aswad, Mark Robert Keezer, Dang Khoa Nguye. Use of non-medical cannabis in epilepsy: A scoping review. Frontiers in neurology. vol 14. 2023-03-23. PMID:36949852. |
the use of medical cannabis among people with epilepsy (pwe) has been garnering increasing interest. |
2023-03-23 |
2023-08-14 |
Not clear |
| Dagmar Koethe, Cathrin Rohleder, Lutz Kracht, F Markus Lewek. Cannabidiol enhances cerebral glucose utilization and ameliorates psychopathology and cognition: A case report in a clinically high-risk mental state. Frontiers in psychiatry. vol 14. 2023-03-20. PMID:36937734. |
cannabidiol is a promising compound carrying an orphan drug approval for rare certain childhood epilepsy types and is under investigation as an antipsychotic compound with a new mechanism of action compared to existing antipsychotics. |
2023-03-20 |
2023-08-14 |
Not clear |
| Darina Georgieva, James Langley, Katherine Hartkopf, Lisa Hawk, Amanda Margolis, Aaron Struck, Elizabeth Felton, David Hsu, Barry E Gida. Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex® (cannabidiol) in patients with refractory epilepsy. Epilepsy & behavior : E&B. vol 141. 2023-03-09. PMID:36893722. |
real-world, long-term evaluation of the tolerability and therapy retention of epidiolex® (cannabidiol) in patients with refractory epilepsy. |
2023-03-09 |
2023-08-14 |
Not clear |
| Erica Braun, Francesca M Gualano, Prabha Siddarth, Eric Sega. Second-line cannabis therapy in patients with epilepsy. Clinical neurology and neurosurgery. vol 227. 2023-03-04. PMID:36870086. |
second-line cannabis therapy in patients with epilepsy. |
2023-03-04 |
2023-08-14 |
Not clear |
| Antonella Riva, Gianluca D'Onofrio, Angelica Pisati, Roberta Roberti, Elisabetta Amadori, Friedrich Bosch, Carolina Fischinger Moura de Souza, Ashley Thomas, Emilio Russo, Pasquale Striano, Allan Baya. Cannabidiol Add-On in Glycosylphosphatidylinositol-Related Drug-Resistant Epilepsy. Cannabis and cannabinoid research. 2023-03-02. PMID:36862522. |
cannabidiol add-on in glycosylphosphatidylinositol-related drug-resistant epilepsy. |
2023-03-02 |
2023-08-14 |
Not clear |
| Se Hee Kim, Han Som Choi, Chung Mo Koo, Bong-Rim Joo, Byung-Joo Park, Hae Kook Lee, Joon Soo Lee, Heung Dong Kim, Hoon-Chul Kan. Erratum: Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy. Journal of clinical neurology (Seoul, Korea). vol 19. issue 2. 2023-02-28. PMID:36854341. |
erratum: effects of cannabidiol on adaptive behavior and quality of life in pediatric patients with treatment-resistant epilepsy. |
2023-02-28 |
2023-08-14 |
Not clear |
| b' George J\\xc3\\xaetc\\xc4\\x83, Bianca E \\xc5\\x90sz, Camil E Vari, Carmen-Maria Rusz, Amelia Tero-Vescan, Amalia Pu\\xc8\\x99ca\\xc8\\x9. Cannabidiol: Bridge between Antioxidant Effect, Cellular Protection, and Cognitive and Physical Performance. Antioxidants (Basel, Switzerland). vol 12. issue 2. 2023-02-25. PMID:36830042.' |
the literature provides scientific evidence for the beneficial effects of cannabidiol (cbd), and these effects extend beyond epilepsy treatment (e.g., lennox-gastaut and dravet syndromes), notably the influence on oxidative status, neurodegeneration, cellular protection, cognitive function, and physical performance. |
2023-02-25 |
2023-08-14 |
Not clear |
| Danielle McDermott, Marielle L Darwin, Kirsten Fetrow, Ian Coulter, Kristal Biesecker, John A Thompso. Cannabis use patterns in drug-resistant and pharmacoresponsive epilepsy: Single tertiary referral center survey investigation. PloS one. vol 18. issue 1. 2023-01-27. PMID:36706124. |
cannabis use patterns in drug-resistant and pharmacoresponsive epilepsy: single tertiary referral center survey investigation. |
2023-01-27 |
2023-08-14 |
Not clear |
| Danielle McDermott, Marielle L Darwin, Kirsten Fetrow, Ian Coulter, Kristal Biesecker, John A Thompso. Cannabis use patterns in drug-resistant and pharmacoresponsive epilepsy: Single tertiary referral center survey investigation. PloS one. vol 18. issue 1. 2023-01-27. PMID:36706124. |
this study sought to identify differences in cannabis use and perceptions about cannabis in mitigating seizure-related symptoms in patients with epilepsy, and to evaluate differences in these patterns between drug-resistant versus pharmacoresponsive epilepsy. |
2023-01-27 |
2023-08-14 |
Not clear |
| Danielle McDermott, Marielle L Darwin, Kirsten Fetrow, Ian Coulter, Kristal Biesecker, John A Thompso. Cannabis use patterns in drug-resistant and pharmacoresponsive epilepsy: Single tertiary referral center survey investigation. PloS one. vol 18. issue 1. 2023-01-27. PMID:36706124. |
a collection of self-report surveys completed by patients with epilepsy (n = 76) were used to retrospectively compare differences in those with drug-resistant versus pharmacoresponsive epilepsy regarding 1) proportion who used cannabis, 2) frequency of use, 3) method of use, and 4) reason for use. |
2023-01-27 |
2023-08-14 |
Not clear |
| Danielle McDermott, Marielle L Darwin, Kirsten Fetrow, Ian Coulter, Kristal Biesecker, John A Thompso. Cannabis use patterns in drug-resistant and pharmacoresponsive epilepsy: Single tertiary referral center survey investigation. PloS one. vol 18. issue 1. 2023-01-27. PMID:36706124. |
results from this study highlight the need for epilepsy providers to formally assess patients' perceptions and use of non-prescribed cannabis to inform clinical care decisions, particularly in the drug-resistant epilepsy population. |
2023-01-27 |
2023-08-14 |
Not clear |
| Lyndsey L Anderson, Dilara A Bahceci, Nicole A Hawkins, Declan Everett-Morgan, Samuel D Banister, Jennifer A Kearney, Jonathon C Arnol. Heterozygous deletion of Gpr55 does not affect a hyperthermia-induced seizure, spontaneous seizures or survival in the Scn1a+/- mouse model of Dravet syndrome. PloS one. vol 18. issue 1. 2023-01-26. PMID:36701411. |
a purified preparation of cannabidiol (cbd), a cannabis constituent, has been approved for the treatment of intractable childhood epilepsies such as dravet syndrome. |
2023-01-26 |
2023-08-14 |
mouse |
| Fabienne Kühne, Lena-Luise Becker, Thomas Bast, Astrid Bertsche, Ingo Borggraefe, Christian Malte Boßelmann, Jörg Fahrbach, Christoph Hertzberg, Nina A Herz, Martin Hirsch, Martin Holtkamp, Christine Janello, Gerhard Josef Kluger, Gerhard Kurlemann, Holger Lerche, Konstantin L Makridis, Felix von Podewils, Milka Pringsheim, Susanne Schubert-Bast, Juliane Schulz, Andreas Schulze-Bonhage, David Steinbart, Bernhard J Steinhoff, Adam Strzelczyk, Steffen Syrbe, Heike De Vries, Christiane Wagner, Johanna Wagner, Bernd Wilken, Christine Prager, Kerstin A Klotz, Angela M Kaind. Real world data on cannabidiol treatment of various epilepsy subtypes: a retrospective, multicenter study. Epilepsia open. 2023-01-24. PMID:36693811. |
real world data on cannabidiol treatment of various epilepsy subtypes: a retrospective, multicenter study. |
2023-01-24 |
2023-08-14 |
Not clear |
| Cindy H T Yeung, Jessica L Beers, Klarissa D Jackson, Andrea N Edginto. Verifying in vitro-determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically based pharmacokinetic modelling. CPT: pharmacometrics & systems pharmacology. 2022-12-21. PMID:36540909. |
cannabidiol (cbd) is approved for treatment of seizures associated with two forms of epilepsy that become apparent in infancy or early childhood. |
2022-12-21 |
2023-08-14 |
human |
| Jerzy P Szaflarski, Orrin Devinsky, Merrick Lopez, Yong D Park, Pilar Pichon Zentil, Anup D Patel, Elizabeth A Thiele, Robert T Wechsler, Daniel Checketts, Farhad Sahebka. Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: 4-year results from the expanded access program. Epilepsia. 2022-12-20. PMID:36537757. |
long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: 4-year results from the expanded access program. |
2022-12-20 |
2023-08-14 |
Not clear |
| Jerzy P Szaflarski, Orrin Devinsky, Merrick Lopez, Yong D Park, Pilar Pichon Zentil, Anup D Patel, Elizabeth A Thiele, Robert T Wechsler, Daniel Checketts, Farhad Sahebka. Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: 4-year results from the expanded access program. Epilepsia. 2022-12-20. PMID:36537757. |
cannabidiol (cbd) expanded access program (eap), initiated in 2014, provided add-on cbd to patients with treatment-resistant epilepsy (tre) at 35 us epilepsy centers. |
2022-12-20 |
2023-08-14 |
Not clear |
| Simon Erridge, Carl Holvey, Ross Coomber, Jonathan Hoare, Shaheen Khan, Michael Platt, James Rucker, Mark Weatherall, Sushil Beri, Mikael Sodergre. Clinical Outcome Data of Children Treated with Cannabis Based Medicinal Products for Treatment Resistant Epilepsy - Analysis from the UK Medical Cannabis Registry. Neuropediatrics. 2022-12-20. PMID:36539215. |
clinical outcome data of children treated with cannabis based medicinal products for treatment resistant epilepsy - analysis from the uk medical cannabis registry. |
2022-12-20 |
2023-08-14 |
Not clear |
| Hakan Silek, Ozgur Bilgin Topcuogl. Analysis of YouTube videos as a source of information for reliability and effectiveness of cannabidiol oil in treatment of epilepsy. Epilepsy & behavior : E&B. vol 138. 2022-12-15. PMID:36473301. |
analysis of youtube videos as a source of information for reliability and effectiveness of cannabidiol oil in treatment of epilepsy. |
2022-12-15 |
2023-08-14 |
Not clear |
| Hakan Silek, Ozgur Bilgin Topcuogl. Analysis of YouTube videos as a source of information for reliability and effectiveness of cannabidiol oil in treatment of epilepsy. Epilepsy & behavior : E&B. vol 138. 2022-12-15. PMID:36473301. |
cannabidiol (cbd) oil has been used for the treatment of refractory epilepsy for a long time. |
2022-12-15 |
2023-08-14 |
Not clear |